RAPORT ESPI 15/2021 | 16-04-2021 | Nadanie systemowi PCR|ONE panel MRSA/MSSA znaku CE-IVD

Previous PostRAPORT ESPI 14/2021 | 06-04-2021 | Otrzymanie zawiadomienia, o którym mowa w art. 19 ust. 1 MARNext PostRAPORT ESPI 16/2021 | 16-04-2021 | Otrzymanie pozytywnej rekomendacji dot. wydania certyfikatu zgodności z normą ISO 13485:2016 dla Bacteromic sp. z o.o.

0Shares

01.04.2025

Scope Fluidics Named “Stock Exchange Company of the Year 2024″ by Puls Biznesu

lk0

08.01.2025

Scope Fluidics Reports Positive Results from Software Development for Rapid Detection

lk0

08.01.2025

EAP Results Confirm Readiness for BACTEROMIC System Market Deployment

lk0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 272 593,00 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Życzenia

RAPORT ESPI 15/2021 | 16-04-2021 | Nadanie systemowi PCR|ONE panel MRSA/MSSA znaku CE-IVD

Related Posts

Scope Fluidics Named “Stock Exchange Company of the Year 2024″ by Puls Biznesu

Scope Fluidics Reports Positive Results from Software Development for Rapid Detection

EAP Results Confirm Readiness for BACTEROMIC System Market Deployment